Company: SHPH
Filing Date: 2025-12-11
Form Type: S-1/A
Source: 0001493152-25-027310
Chunk: 7

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-12-11
Form: S-1/A
Chunk 7
---
 heading “Risk Factors” contained in our most recent annual report on Form 10-K filed with the SEC, and as incorporated by reference in this prospectus, as the same may be amended, supplemented or superseded by the risks and uncertainties described under similar headings in the other documents that are filed by us after the date hereof and incorporated by reference into this prospectus. Please also read carefully the section below titled “Cautionary Note Regarding Forward-Looking Statements.”

The sale of a substantial amount of our common stock, including resale of the shares of common stock by the selling stockholder in the public market, could adversely affect the market price of our common stock.

We are registering for resale 625,156 shares of common stock issuable upon the exercise of a pre-funded warrant held by the selling stockholder. Sales of substantial amounts of our common stock in the public market, or the perception that such sales might occur, could adversely affect the market price of our common stock. We cannot predict if and when the selling stockholder may sell such shares in the public market.

Recent and future acquisitions may have a material adverse effect on our ability to manage our business and our results of operations and financial condition.

We may acquire assets,
businesses, technologies, services, or products which are complementary to our operations. Recent and future acquisitions, including
the now complete asset acquisition pursuant to the Asset Purchase Agreement with 1563868 B.C. Ltd., a Canadian limited corporation, and
the Company’s wholly owned subsidiary, 1542770 BC Ltd., a Canadian limited corporation, and the related employment contract with
Zhitian (Andy) Zhang, an individual residing in Vancouver, Canada (the “Asset Purchase”), may expose us to potential risks,
including risks associated with not receiving the intended benefits of the Asset Purchase, the diversion of resources and management
attention from our existing business and technology, the costs and expenses incurred in connection with such acquisitions, or the potential
loss of or harm to relationships with suppliers, employees, and potential customers resulting from our integration of a new asset class.
If any of these risks were to occur, our operations could be materially and adversely affected.

If we are unable to acquire and retain new customers for our Molecule.ai platform or if those customers renew licenses at lower prices, our future revenues may be negatively impacted.

We expect to derive a
significant portion of our revenues from license agreements related to our Molecule.ai platform. As a result, acquiring new customers
and maintaining the renewal rate of those new customers